TIL vs. DTIL, ELUT, JATT, CGTX, ATHA, IKNA, GRTS, CVM, PASG, and TSBX
Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include Precision BioSciences (DTIL), Elutia (ELUT), JATT Acquisition (JATT), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), Ikena Oncology (IKNA), Gritstone bio (GRTS), CEL-SCI (CVM), Passage Bio (PASG), and Turnstone Biologics (TSBX). These companies are all part of the "biological products, except diagnostic" industry.
Precision BioSciences (NASDAQ:DTIL) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
Precision BioSciences has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.
Precision BioSciences has higher revenue and earnings than Instil Bio. Precision BioSciences is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Precision BioSciences had 12 more articles in the media than Instil Bio. MarketBeat recorded 12 mentions for Precision BioSciences and 0 mentions for Instil Bio. Precision BioSciences' average media sentiment score of 1.32 beat Instil Bio's score of 0.37 indicating that Instil Bio is being referred to more favorably in the news media.
Instil Bio received 5 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 66.92% of users gave Precision BioSciences an outperform vote while only 51.98% of users gave Instil Bio an outperform vote.
38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 5.1% of Precision BioSciences shares are owned by insiders. Comparatively, 54.7% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Instil Bio has a net margin of 0.00% compared to Instil Bio's net margin of -125.84%. Precision BioSciences' return on equity of -58.49% beat Instil Bio's return on equity.
Precision BioSciences currently has a consensus target price of $46.33, suggesting a potential upside of 338.35%. Instil Bio has a consensus target price of $36.00, suggesting a potential upside of 220.00%. Given Instil Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Precision BioSciences is more favorable than Instil Bio.
Summary
Precision BioSciences beats Instil Bio on 10 of the 17 factors compared between the two stocks.
Get Instil Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Instil Bio Competitors List
Related Companies and Tools
